Viewing Study NCT06363734

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 2:19 AM

Ignite Modification Date: 2025-12-29 @ 9:25 AM

Study NCT ID: NCT06363734

Status: RECRUITING

Last Update Posted: 2024-04-16

First Post: 2024-04-09

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module